Budget Impact Analysis of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Event

被引:18
作者
Alsumali, Adnan [1 ]
Lautsch, Dominik [1 ]
Liu, Rongzhe [2 ]
Patel, Dipen [2 ]
Nanji, Sakina [2 ]
Djatche, Laurence M. [1 ]
机构
[1] Merck & Co Inc, Ctr Observat & Real World Evidence, Kenilworth, NJ 07033 USA
[2] Pharmerit, Bethesda, MD USA
关键词
Budget impact; Cost analysis; Heart failure with reduced ejection fraction; Vericiguat; Worsening heart failure; OUTCOMES; CARE; MORTALITY; COSTS;
D O I
10.1007/s12325-021-01681-2
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Introduction In the USA, patients with chronic heart failure (HF) with reduced ejection fraction (HFrEF) following a worsening HF event (WHFE) have significantly increased healthcare resource use and medical costs. This analysis aimed to estimate the budget impact of vericiguat as an add-on therapy to guideline-directed medical therapy (GDMT) for the treatment of chronic HFrEF following a WHFE from a US commercial payer perspective. Methods A model was developed to estimate the budget impact of adding vericiguat to the formulary by comparing a current scenario (GDMT) and a new scenario (vericiguat plus GDMT) to a hypothetical 10-million-member commercial payer over a 3-year time horizon. Epidemiology data was obtained from literature. Treatment utilization rates of GDMT and clinical inputs (HF hospitalization and cardiovascular [CV] morality) were based on the VICTORIA trial in which patients with chronic HFrEF following a WHFE were randomized to GDMT plus placebo or GDMT plus vericiguat. Costs (2020 US$) included drug acquisition, hospitalization, routine care, and mortality. Results Approximately 20,510 prevalent cases in year 1 and 3109 annual incident cases in subsequent years were estimated to be eligible for treatment with vericiguat. At a utilization rate of 5%, 10%, and 15% for vericiguat over years 1-3, the per member per month (PMPM) budget impact was estimated to be $0.048, $0.064, and $0.086, respectively, associated with 44, 32, and 30 fewer HF hospitalizations and 7, 12, and 18 fewer CV deaths, respectively. Reduction in HF hospitalizations and CV deaths reduced the budget impact by 14% in total over 3 years. Conclusion Adding vericiguat to commercial plan formulary was associated with limited budget impact, primarily driven by drug acquisition costs but partially offset by reduced cost of HF hospitalizations and CV deaths.
引用
收藏
页码:2631 / 2643
页数:13
相关论文
共 33 条
  • [1] [Anonymous], 2019, ENTRESTO PRESCR INF
  • [2] [Anonymous], 2008, ALDACTONE PRESCR INF
  • [3] [Anonymous], 2019, PRINIVIL PRESCR INF
  • [4] [Anonymous], 2017, COREG PRESCRIBING IN
  • [5] Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction
    Armstrong, Paul W.
    Pieske, Burkert
    Anstrom, Kevin J.
    Ezekowitz, Justin
    Hernandez, Adrian F.
    Butler, Javed
    Lam, Carolyn S. P.
    Ponikowski, Piotr
    Voors, Adriaan A.
    Jia, Gang
    McNulty, Steven E.
    Patel, Mahesh J.
    Roessig, Lothar
    Koglin, Joerg
    O'Connor, Christopher M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) : 1883 - 1893
  • [6] Benjamin EJ, 2019, CIRCULATION, V139, pE56, DOI [10.1161/CIR.0000000000000659, 10.1161/CIR.0000000000000746]
  • [7] Budget Impact of Adding Ivabradine to Standard of Care in Patients with Chronic Systolic Heart Failure in the United States
    Borer, Jeffrey S.
    Kansal, Anuraag R.
    Dorman, Emily D.
    Krotneva, Stanimira
    Zheng, Ying
    Patel, Harshali K.
    Tavazzi, Luigi
    Komajda, Michel
    Ford, Ian
    Boehm, Michael
    Kielhorn, Adrian
    [J]. JOURNAL OF MANAGED CARE & SPECIALTY PHARMACY, 2016, 22 (09) : 1064 - 1071
  • [8] Pharmacotherapy Treatment Patterns, Outcomes, and Health Resource Utilization Among Patients with Heart Failure with Reduced Ejection Fraction at a US Academic Medical Center
    Bress, Adam P.
    King, Jordan B.
    Brixner, Diana
    Kielhorn, Adrian
    Patel, Harshali K.
    Maya, Juan
    Lee, Vinson C.
    Biskupiak, Joseph
    Munger, Mark
    [J]. PHARMACOTHERAPY, 2016, 36 (02): : 174 - 186
  • [9] Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event
    Butler, Javed
    Djatche, Laurence M.
    Sawhney, Baanie
    Chakladar, Sreya
    Yang, Lingfeng
    Brady, Joanne E.
    Yang, Mei
    [J]. ADVANCES IN THERAPY, 2020, 37 (09) : 4015 - 4032
  • [10] Butler J, 2020, J AM COLL CARDIOL, V75, P1014